XUHC:F:F-Xtrackers (IE) Public Limited Company - Xtrackers MSCI USA Health Care UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 53.95

Change

-0.06 (-0.11)%

Market Cap

USD 0.85B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-21 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

+0.10 (+0.39%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

N/A

USD 117.80B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

+0.14 (+0.26%)

USD 92.18B
SXR8:F iShares Core S&P 500 UCITS ETF..

+2.58 (+0.49%)

USD 85.13B
FRCJ:F UBS MSCI Japan Socially Respon..

+0.07 (+0.30%)

USD 75.40B
EUNL:F iShares Core MSCI World UCITS ..

-0.08 (-0.08%)

USD 72.04B
XDNY:F Xtrackers MSCI Japan ESG Scree..

N/A

USD 56.70B
SXRZ:F iShares VII PLC - iShares Nikk..

N/A

USD 55.70B
VUAA:F Vanguard S&P 500 UCITS Acc

+0.58 (+0.60%)

USD 51.63B
VUSA:F Vanguard Funds Public Limited ..

+0.75 (+0.79%)

USD 51.63B

ETFs Containing XUHC:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.53% 56% F 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.53% 54% F 55% F
Trailing 12 Months  
Capital Gain 10.01% 52% F 61% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.01% 50% F 54% F
Trailing 5 Years  
Capital Gain 71.43% 80% B- 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 71.43% 79% B- 62% D
Average Annual (5 Year Horizon)  
Capital Gain 10.71% 83% B 76% C+
Dividend Return 10.71% 82% B 70% C-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 10.71% 58% F 81% B-
Risk Adjusted Return 99.97% 98% N/A 97% N/A
Market Capitalization 0.85B 71% C- 56% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike